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Abstract
Background Endoscopic retrograde cholangiopancreatography (ERCP) requires moderate to deep sedation, usually with 
propofol. Adverse effects of propofol sedation are relatively common, such as respiratory and cardiovascular depression. 
This study was conducted to determine if doxapram, a respiratory stimulant, could be used to reduce the incidence of res-
piratory depression.
Methods This is a single-center, prospective randomized double-blind study performed in the endoscopy unit of Helsinki 
University Central Hospital. 56 patients were randomized in a 1:1 ratio to either receive doxapram as an initial 1 mg/kg bolus 
and an infusion of 1 mg/kg/h (group DOX) or placebo (group P) during propofol sedation for ERCP. Main outcome measures 
were apneic episodes and hypoxemia  (SpO2 < 90%). Mann–Whitney test for continuous variables and Fisher’s exact test for 
discrete variables were used and mixed effects modeling to take into account repeated measurements on the same subject 
and comparing both changes within a group as a function of time and between the groups.
Results There were no statistically significant differences in apneic episodes (p = 0.18) or hypoxemia (p = 0.53) between the 
groups. There was a statistically significant rise in  etCO2 levels in both groups, but the rise was smaller in group P. There was 
a statistically significant rise in Bispectral Index (p = 0.002) but not modified Observer’s Assessment of Agitation/Sedation 
(p = 0.21) in group P. There were no statistically significant differences in any other measured parameters.
Conclusions Doxapram was not effective in reducing respiratory depression caused by deep propofol sedation during ERCP. 
Further studies are warranted using different sedation protocols and dosing regimens.
Clinical trial registration ClinicalTrials.gov ID NCT02171910.
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Endoscopic retrograde cholangiopancreatography (ERCP) is 
a very demanding endoscopic procedure that usually cannot 
be performed without deep sedation or general anesthesia 
because of substantial procedural discomfort and pain [1–3]. 
There is no agreement on the best method of anesthetic care 
for ERCP. Traditionally, benzodiazepines and opioids were 
used but propofol has been gaining popularity around the 
world for the past few decades [4]. Propofol sedation is not 
without risks [5], one of the most important of which is 
respiratory depression and hypoxemia.
Doxapram (1-ethyl-4-(2-morpholin-4-ylethyl)-3,3-di-
phenyl-pyrrolidin-2-one), a central and peripheral respira-
tory stimulant and a non-specific stimulant of the central 
nervous system, has been widely used to reverse respiratory 
depression [6, 7]. Doxapram has recently been shown to 
shorten the time to spontaneous breathing after total intra-
venous anesthesia using propofol and remifentanil [8]. To 
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our knowledge, there are only a few studies [9–12] done on 
humans on the effect of doxapram during sedation, but none 
of them investigated the use of doxapram with propofol dur-
ing endoscopic sedation.
In our preliminary tests, doxapram showed promis-
ing results. However, these tests were not randomized or 
blinded. Therefore, this study was carried out to assess the 
efficacy of doxapram as an additive to deep propofol seda-
tion in reducing the incidence of respiratory depression in 
a randomized double-blinded protocol. The study was con-
ducted in the endoscopic unit of Meilahti Hospital, a ter-
tiary university clinic, where over 1200 ERCP procedures 
are performed annually.
Materials and methods
This study was approved by the institutional Ethics Com-
mittee of Helsinki University Central Hospital (Ethics 
Committee, Department of Surgery, Biomedicum Hel-
sinki 2 C, Tukholmankatu 8 C, PL 705, 00029 HUS, Fin-
land. DNRO 281/13/03/2013) on January 22, 2014. This 
study was registered in The EudraCT system (EudraCT 
2013-003873-85) and approved by the Finnish Medicines 
Agency on April 12, 2016. The study was also registered 
in the ClinicalTrials.gov registry (ClinicalTrials.gov ID 
NCT02171910).
According to a power analysis performed before the 
study, at least 18 patients per group were required to detect 
a 30% difference in respiratory depression between the 
groups (β = 0.1, α < 0.05). A total of 56 patients scheduled 
for an ERCP procedure from November to December 2016 
were enrolled in the study. Exclusion criteria were age > 75, 
epilepsy, coronary artery disease (stable or unstable angina 
pectoris), chronic obstructive pulmonary disease, acute alco-
hol withdrawal syndrome, allergy to propofol, or doxapram.
Patients were randomized at the ratio of 1:1 into two 
groups, according to a computer-generated table of ran-
dom numbers to receive doxapram (group DOX) or pla-
cebo (group P) in a double-blind manner. The patient and 
the anesthesiologist who was also responsible for the data 
collection were blinded to the study drug administered.
Propofol (10 mg/ml) infusion was given 0.5 ml/kg/h 
(83.3 µg/kg/min). Before the infusion, the patients’ pharynx 
received topical anesthesia with lidocaine spray (Xylocaine 
10 mg/dos®, 5 sprays), alfentanil 0.5 mg i.v., glycopyrro-
nium 0.2 mg i.v., and lidocaine 20 mg i.v. Endoscope was 
inserted once Bispectral index (BiS) was < 60. In the group 
DOX, the patient received an initial bolus of doxapram 
10 mg/ml 0.1 ml/kg and an infusion of doxapram 10 mg/
ml at 0.1 ml/kg/h. The group P received an initial bolus on 
9 g/l NaCl solution 0.1 ml/kg and an infusion of 9 g/l NaCl 
solution at 0.1 ml/kg/h. During the procedure, propofol infu-
sion was adjusted by 10 ml/h increments in order to keep 
BiS < 60 or modified Observer’s Assessment of Alertness/
Sedation (mOAAS) at level 1–2.
If peripheral oxygen saturation  (SpO2) was < 88% or 
if the patient stopped breathing, patients in both groups 
were given doxapram 1 mg/kg i.v. openly. The dose could 
be repeated if needed. If breathing would not start despite 
doxapram, the procedure was to be paused and mask ven-
tilation commenced. After the patient started breathing 
again, the procedure could continue, and sedation would 
be continued using propofol boluses of 10–20 mg i.v. and 
the study would be stopped for the patient in question.
The following data of each patient were registered in a 
prospective manner: age, weight, height, American Society 
of Anesthesiology physical status classification (ASA), per-
formed procedures, duration of the procedure, consumption 
of propofol, doxapram, or placebo. Heart rate, rate of breath-
ing,  SpO2, end-tidal  CO2  (etCO2), and non-invasive blood 
pressure (NIBP) were recorded at 5-min intervals during 
the procedure. The level of sedation was assessed using BiS 
and mOAAS at 5-min intervals during the procedure [13]. 
Use of phenylephrine or atropine was recorded. The satisfac-
tion of the endoscopist to the sedation (ease of inserting the 
endoscope, patient co-operation (low number when lightly 
sedated (optimally), high when deeply sedated by defini-
tion), gagging, coughing, belching, distracting movement 
by the patient using a 4 step scale from none to plenty, and 
difficulty of the procedure by The Schutz scale [14] was 
recorded.
During recovery, patient vital signs (heart rate,  SpO2, 
non-invasive blood pressure), pain intensity (verbal rat-
ing scale, 0 = no pain and 4 = severe pain), sedation level 
(Gillham score) [15], and recovery rapidity (Aldrete 
score) [16, 17] were registered at 5-min intervals until 
discharge. Postprocedural nausea, if present, was treated 
and registered. Before discharge from the recovery room, 
patients were asked about their satisfaction with the seda-
tion. A seven-step numeric scale (1 = very unsatisfied, 
7 = very satisfied) was applied for the measurement of 
patient satisfaction with sedation [18]. An Aldrete score 
of ≥ 9 and mild pain as the maximum were defined as 
discharge criteria.
Main outcome measures were apneic episodes and hypox-
emia defined as  SpO2 < 90%. Secondary outcome measures 
were as follows:
1. SpO2, blood pressure, heart rate, rate of breathing and 
end-tidal  CO2, BiS and mOAAS, during the procedure,
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2. blood pressure, heart rate, rate of breathing, pain inten-
sity, Gilham score, and Aldrete score during recovery,
3. patient and endoscopist satisfaction.
The results are reported as mean and standard devia-
tion (mean [SD]) or median and interquartile range (IQR). 
The possible differences between groups were tested with 
the Mann–Whitney test for continuous variables and with 
the Fisher’s exact test for discrete variables. Mixed effects 
modeling was used to take into account repeated measure-
ments on the same subject and comparing results between 
the groups. Linear model was used for continuous variables 
and multinomial logistic regression model for ordinal vari-
ables. Both changes within a group as a function of time 
and differences between the groups were taken into account. 
There were enough data points for statistical analysis from 
the beginning of the procedure to 30 min into the procedure. 
Groups were also analyzed in separate mixed effects model 
to obtain the possible linear time dependency within the 
group. Statistical calculations were generated using IBM 
SPSS Statistics 24 (International Business Machines Cor-
poration, Endicott, NY, USA).
Results
A total of 56 patients were recruited to the study. A CON-
SORT diagram is presented in Fig. 1. Demographics, drug 
consumption, and ERCP details are shown in Table 1. There 
were no statistically significant differences between the 
groups.
Primary outcome measures
Seventeen patients in group P and 11 patients in group DOX 
had apneic episodes. There were no statistically significant 
differences between the groups (p = 0.18). Hypoxemia was 
recorded on 5 patients in group P and 8 patients in group 
DOX, with no statistically significant difference (p = 0.53). 
The procedure had to be paused once in group DOX because 
of hypoxemia, and the procedure was delayed once for the 
same reason after induction of sedation. Both times mask 
ventilation was required. There was no need for mask ven-
tilation or pauses in procedure in group P. The amount of 
doxapram given as infusion in the DOX group was 113.8 
(34.1) mg, and additional doxapram boluses were given 3 
times in group P and once in group DOX, with no statisti-
cally significant difference (p = 0.61).
Secondary outcome measures
SpO2 and  etCO2 levels during procedure are shown in Figs. 2 
and 3 respectively. Results of the mixed effects model-to-
model linear time dependence analysis of secondary out-
come measures during the procedure are shown in Table 2. 
There was a statistically significant rise in  etCO2 levels in 
both groups, and the rise was smaller in group P than in 
Fig. 1  Consort 2010 flow 
diagram
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doxapram group (Table 3). There was a statistically signifi-
cant rise in BiS in both groups (Table 2) but not mOAAS.
There were no other statistically significant differences 
between the groups in any of the measured parameters dur-
ing recovery.
There were no statistically significant differences between 
the groups in endoscopist and patient satisfaction (Table 1).
Discussion
In this placebo-controlled, double-blind, and randomized 
study, no differences were found between placebo and 
doxapram regarding the alleviation of respiratory depres-
sion. It may be that the dosage used was too small to 
counteract the respiratory depression caused by deep 
Table 1  Demographics, 
propofol consumption, ERCP 
indications, and performed 
procedures in patients receiving 
doxapram or placebo
a Patient may have several indications and procedures
ASA American Society of Anesthesiologists physical status classification system, BMI Body Mass Index, 






Age; years median (range) 51 (19–70) 48 (20–68) 0.93
Male/female 17(51%)/11 (39%) 16 (57%)/12 (43%) 1.0
BMI kg/m2 (median, range) 23.9 (14.7–33) 25.7 (18–34.6) 0.21
Length of the procedure min (median, range) 22 (3–52) 20 (5–51) 0.81
ASA I–II 21 (75%) 20 (71%) 0.76
ASA III–IV 7 (25%) 8 (29%)
Propofol consumption, milligrams 368.35 (229.56) 353.83 (116.16) 0.40
procedure duration, minutes median (IQR) 22.71 (13.70) 23.43 (10.91) 0.63
Patient satisfaction, median (IQR) 6.57 (0.50) 6.67 (0.55) 0.21
Endoscopist satisfaction, median (IQR) 7.29 (1.46) 7.14 (1.24) 0.26
ERCP  indicationa
 Common bile duct stones 0 3 (10%) 0.24
 Biliary stricture 4 (14%) 6 (21%) 0.73
 Primary sclerosing cholangitis 15 (54%) 10 (32%) 0.18
 Postoperative biliary leak 1 (4%) 1 (4%) 1.0
 Liver transplantation and stricture 1 (4%) 2 (7%) 1.0
 Chronic pancreatitis/pseudocyst 9 (32%) 6 (21%) 0.33
Procedurea
 Biliary cytology 17 (61%) 13 (46%) 0.28
 Biliary sphincterotomy 7 (25%) 6 (21%) 0.75
 CBD stone extraction 0 3(10%) 0.24
 Biliary dilatation 4 (14%) 4 (14%) 1.0
 Biliary stent application, exchange or removal 6 (21%) 5 (17%) 1.0
 Pancreatic sphincterotomy 2 (7%) 1 (4%) 0.53
 Pancreatic cytology 1 (4%) 1 (4%) 1.0
 Pancreatic dilatation 6 (21%) 1 (4%) 0.10
 Pancreatic stent application, exchange or removal 9 (32%) 6 (21%) 0.54
 Pseudocystogastrostomy/duodenostomy 0 1 (4%) 1.0
Single operator cholangioscopy 0 2 (7%) 0.49
 ERCP degree of difficulty 0.266
  I 9 (32%) 11 (39%)
  II 7 (25%) 5 (18%)
  III 12 (43%) 9 (32%)
  IV 0 3 (11%)
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propofol sedation and a larger dose might give a more 
favorable outcome. While the dosage for boluses of 
doxapram we used was in line with previous studies [6, 
19], there are no studies where doxapram was used as an 
infusion during a procedure, only after. Therefore, we 
decided to use a low dosage for the infusion considering 
the possible analeptic effect of doxapram. The dosage 
is the lowest starting dose for worsening of COPD. It 
would be possible to increase the dose considerably as it 
is far from toxic levels of 130 mg/kg/day and lower than 
the dosage recommended for apnea of the newborn of 
2–2.5 mg/kg/h [6].
It is also possible that the definition of hypoventilation 
used in this study was not optimal. While hypoxemia is 
undoubtedly a valid marker of hypoventilation, it does 
not differentiate a milder form of hypoventilation from 
normoventilation.  EtCO2 measurement we used is not 
reliable either in this regard since it was measured from a 
nostril next to the nasal oxygen cannula. If the patient was 
breathing through their mouth the measured levels may 
be far lower than actual  etCO2 levels. Another confound-
ing factor is  CO2 insufflation used by the endoscopist 
which is occasionally expelled by the patient causing sig-
nificantly heightened measured levels of  etCO2. Trans-
cutaneous  CO2 measurement could have revealed a more 
detailed picture of ventilatory status.
While there were no statistically significant differences in 
weight or drug consumption between the groups, the patients 
in group P weighed more and consequently received more 
propofol. While the dosage was weight dependent, it could 
influence the results as the dosage was administered accord-
ing to absolute weight and not ideal or lean body weight.
Fig. 2  Peripheral oxygen satura-
tion levels during ERCP
Fig. 3  End-tidal CO2 levels 
during ERCP
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Historically doxapram has been used as an analeptic 
drug in conjunction with both volatile and intravenous 
anesthetics due its stimulatory effect on the nervous sys-
tem [20, 21]. Especially with regard to volatile anesthet-
ics, this effect has been attributed to increased rate of 
breathing caused by the respiratory stimulant effect of 
the drug [22]. Since the arousal effect is also seen with 
intravenous anesthetics, this would suggest also a direct 
central nervous stimulatory effect. This arousal caused 
by doxapram was not seen in this study as the require-
ment for propofol and sedation levels were similar in 
both groups. As such, doxapram does not seem to impair 
propofol sedation.
Even though our hypothesis of less hypoxemia with 
doxapram was not confirmed in this study, one should 
note that while it was not statistically significant, there 
were more patients requiring additional doxapram boluses 
in group P than group DOX. As such, a larger trial might 
have yielded different results favoring doxapram. It is 
possible that doxapram would be more effective when 
given as a bolus when needed should respiratory depres-
sion occur and not as a prophylactic infusion. Perhaps a 
randomized placebo-controlled study in this setting would 
find more favorable results.
Doxapram is rather an old compound and its use has 
declined with the advent of newer fast acting sedatives and 
anesthetics. Still, it remains a quite potent respiratory stimu-
lant that may well be considered to facilitate upper gastro-
intestinal endoscopic procedures in case of sedation-related 
respiratory depression even though it was shown be ineffi-
cient as a prophylactic measure when applied as an infusion. 
Naturally, sedation providers need to be aware of this option 
to be able to take advantage of it and research such as this 
may help clinicians keep in mind older drugs that are not as 
widely used anymore.
This study did not find doxapram to be efficient in reducing 
hypoxemia during deep propofol sedation for ERCP in general 
but that does not mean that there are not some subgroups of 
patients such as patients with chronic pulmonary or neurologic 
diseases that might gain benefit from doxapram in this setting 
and so further research on this topic is still warranted. One 
must also bear in mind that this was a quite small study with 
limited participants and a larger study might yield different 
results. Other limitations for this study are the fact that this was 
a single-center study, so its findings may not be applicable uni-
versally. Also, different sedation protocols may be used with 
doxapram for better results. After all, the sedation used in this 
study was a very deep sedation, close to general anesthesia and 
lighter levels of sedation might result in different outcomes.
Table 2  Mixed effects model-to-model linear time dependence of 
measured variables in different groups during ERCP
Groups are analyzed separately
P Placebo group, Dox Doxapram group, SpO2 peripheral oxygen 
saturation, EtCO2 end-tidal  CO2, mOAAS modified observer’s assess-
ment of alertness/sedation, CI Confidence interval. B (time) shows 
the slope (per min) of the modeled linear time dependence for each 
measured variable
Group Measurement B (time) 95% CI p
Lower Upper
P Heart rate 0.45 0.16 0.73 0.002
Dox Heart rate 0.27 0.09 0.45 0.004
P Breath rate 0.28 0.18 0.38 < 0.001
Dox Breath rate 0.29 0.18 0.40 < 0.001
P SpO2 0.02 − 0.03 0.07 0.515
Dox SpO2 0.04 − 0.01 0.09 0.14
P BIS − 0.51 − 0.78 − 0.24 < 0.001
Dox BIS − 0.76 − 1.11 − 0.40 < 0.001
P EtCO2 0.15 0.06 0.24 0.001
Dox EtCO2 0.05 0.02 0.08 0.001
P mOAAS 0.97 0.93 1.02 0.206
Dox mOAAS 0.96 0.92 1.01 0.087
Table 3  Mixed effects model for  EtCO2, group, and time dependency
EtCO2 end-tidal  CO2, CI confidence interval, meaning of B is stated in the explanation
Variable B 95% CI p Explanation
Lower Upper
Intercept 3.80 3.13 0.04 p < 0.001 Estimated EtCO value of group P at the beginning
Group 0.44 − 0.50 1.38 0.355 Difference between groups at the beginning, group Dox vs group P
Time 0.15 0.08 0.22 p < 0.001 Linear time dependence (slope per min) in group P
Grp × time − 0.10 − 0.19 − 0.01 0.034 Difference in time dependence between group Dox and group P
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